Pulse Biosciences Reports Business Updates and Second Quarter 2026 Financial Results
Pulse Biosciences reported $0.4 million in Q2 revenue and ended the quarter with $101.6 million in cash, bolstered by $46.8 million in ATM net proceeds during the quarter and an additional $10.7 million post-quarter. The company's pivotal NANOPULSE-AF study surpassed 82 evaluable patients, with enrollment now expected to complete by early Q4, three months ahead of schedule, following a protocol expansion to 164 patients.
Key figures
- Cash
- 101600000
- Revenue
- $0.4 million
- Atm shelf
- 125000000
- Q2 atm proceeds
- 46800000
- New atm facility
- 75000000
- Nanopulse af target
- 164
- Post q2 atm proceeds
- 10700000
- Nanopulse af patients
- 82
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.